Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts more than Nifty Microcap 250 and 9.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kilitch Drugs reported audited standalone net profit of Rs 3,239.96 lakhs for FY26, up 4% from Rs 3,115.69 lakhs in FY25. Consolidated net profit stood at Rs 2,950.03 lakhs, up 18.3% from Rs 2,494.01 lakhs. Standalone revenue grew 3.8% to Rs 18,857.43 lakhs, while consolidated revenue increased 18.7% to Rs 23,547.49 lakhs. The company issued bonus shares in 1:1 ratio during Q4, doubling share capital to Rs 3,496.16 lakhs. Statutory auditors issued unmodified (clean) opinion. Borrowings increased significantly from Rs 4,942.40 lakhs to Rs 8,870.90 lakhs. Trade receivables rose sharply from Rs 8,339.83 lakhs to Rs 11,724.43 lakhs. Capital expenditure on PPE/CWIP nearly doubled to Rs 9,503.92 lakhs from Rs 4,687.34 lakhs.
Positive signal with clean audit and profit growth, though growth rates are moderate. The significant increase in borrowings and trade receivables may raise concerns about working capital management and debt levels. EPS appears lower due to bonus share issuance diluting per-share metrics.